22nd Century Group Inc (XXII) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of 22nd Century Group Inc (NYSE:XXII) from a buy rating to a hold rating in a report issued on Friday.

According to Zacks, “22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company’s products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. “

22nd Century Group (XXII) opened at 2.23 on Friday. The company has a 50-day moving average price of $1.90 and a 200 day moving average price of $1.46. The stock’s market cap is $229.15 million. 22nd Century Group has a 52-week low of $0.81 and a 52-week high of $2.84.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by [[site]] and is the property of of [[site]]. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at [[permalink]].

In other news, VP Michael Robert Moynihan sold 29,532 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $2.00, for a total value of $59,064.00. Following the completion of the transaction, the vice president now owns 917,220 shares of the company’s stock, valued at $1,834,440. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Institutional investors have recently bought and sold shares of the stock. Virtu KCG Holdings LLC raised its position in 22nd Century Group by 300.9% in the second quarter. Virtu KCG Holdings LLC now owns 126,106 shares of the biotechnology company’s stock worth $221,000 after buying an additional 94,650 shares in the last quarter. Vanguard Group Inc. increased its stake in 22nd Century Group by 17.6% in the second quarter. Vanguard Group Inc. now owns 2,894,322 shares of the biotechnology company’s stock worth $5,065,000 after buying an additional 432,450 shares during the last quarter. Northern Trust Corp increased its stake in 22nd Century Group by 22.3% in the second quarter. Northern Trust Corp now owns 133,797 shares of the biotechnology company’s stock worth $234,000 after buying an additional 24,401 shares during the last quarter. Finally, National Asset Management Inc. increased its stake in 22nd Century Group by 13.7% in the first quarter. National Asset Management Inc. now owns 172,000 shares of the biotechnology company’s stock worth $204,000 after buying an additional 20,700 shares during the last quarter.

22nd Century Group Company Profile

Get a free copy of the Zacks research report on 22nd Century Group (XXII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com